Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL PSORIASIS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL PSORIASIS TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL PSORIASIS TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.5 PATEINT TREATMENT SUCCESS RATES
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH DERMATOLOGIST
6.8 OTHER KOL SNAPSHOTS
7 REGULATORY SCENARIO
7.1 FDA APPROVALS
7.2 EMA APPROVALS
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
10 MARKET OVERVIEW
10.1 DRIVERS
10.2 RESTRAINS
10.3 OPPURTUNITY
10.4 CHALLENGES
11 GLOBAL PSORIASIS TREATMENT MARKET, BY DISEASE TYPE
11.1 OVERVIEW
11.2 PLAQUE PSORIASIS, BY TREATMENT
11.2.1 MEDICATION
11.2.1.1. CORTICOSTEROIDS
11.2.1.1.1. HYDROCORTISONE, BY BRAND
11.2.1.1.1.1 HYDROCORT
11.2.1.1.1.1.1. MARKET VALUE (USD MN)
A. MARKET VOLUME (IU)
B. AVERAGE SELLING PRICE (USD)
11.2.1.1.1.2 ALPHOSYL
11.2.1.1.1.2.1. MARKET VALUE (USD MN)
11.2.1.1.1.2.2. MARKET VOLUME (IU)
11.2.1.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.1.3 AQUACORT
11.2.1.1.1.3.1. MARKET VALUE (USD MN)
11.2.1.1.1.3.2. MARKET VOLUME (IU)
11.2.1.1.1.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.1.4 OTHERS
11.2.1.1.2. TRIAMCINOLONE, BY BRAND
11.2.1.1.2.1 KENALOG IV
11.2.1.1.2.1.1. MARKET VALUE (USD MN)
11.2.1.1.2.1.2. MARKET VOLUME (IU)
11.2.1.1.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.2.2 ARISTOSPAN
11.2.1.1.2.2.1. MARKET VALUE (USD MN)
11.2.1.1.2.2.2. MARKET VOLUME (IU)
11.2.1.1.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.2.3 TRIVARIS
11.2.1.1.2.3.1. MARKET VALUE (USD MN)
11.2.1.1.2.3.2. MARKET VOLUME (IU)
11.2.1.1.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.2.4 OTHERS
11.2.1.1.3. CLOBETASOL, BY BRAND
11.2.1.1.3.1 TEMOVATE
11.2.1.1.3.1.1. MARKET VALUE (USD MN)
11.2.1.1.3.1.2. MARKET VOLUME (IU)
11.2.1.1.3.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.3.2 CLOBEX
11.2.1.1.3.2.1. MARKET VALUE (USD MN)
11.2.1.1.3.2.2. MARKET VOLUME (IU)
11.2.1.1.3.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.3.3 OLUX
11.2.1.1.3.3.1. MARKET VALUE (USD MN)
11.2.1.1.3.3.2. MARKET VOLUME (IU)
11.2.1.1.3.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.3.4 OTHERS
11.2.1.2. CALCINEURIN INHIBITORS
11.2.1.2.1. TACROLIMUS, BY BRAND
11.2.1.2.1.1 PROGRAF
11.2.1.2.1.1.1. MARKET VALUE (USD MN)
11.2.1.2.1.1.2. MARKET VOLUME (IU)
11.2.1.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.2.1.2 ENVARSUS XR
11.2.1.2.1.2.1. MARKET VALUE (USD MN)
11.2.1.2.1.2.2. MARKET VOLUME (IU)
11.2.1.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.2.1.3 ASTAGRAF XL
11.2.1.2.1.3.1. MARKET VALUE (USD MN)
11.2.1.2.1.3.2. MARKET VOLUME (IU)
11.2.1.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.2.1.4 OTHERS
11.2.1.2.2. PIMECROLIMUS (ELIDEL)
11.2.1.2.2.1.1. MARKET VALUE (USD MN)
11.2.1.2.2.1.2. MARKET VOLUME (IU)
11.2.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.3. IMMUNOSUPPRESSANT
11.2.1.3.1. CYCLOSPORINE, BY BRAND NAME
11.2.1.3.1.1 SANDMMUNE
11.2.1.3.1.1.1. MARKET VALUE (USD MN)
11.2.1.3.1.1.2. MARKET VOLUME (IU)
11.2.1.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.1.2 NEORAL
11.2.1.3.1.2.1. MARKET VALUE (USD MN)
11.2.1.3.1.2.2. MARKET VOLUME (IU)
11.2.1.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.1.3 RESTASIS
11.2.1.3.1.3.1. MARKET VALUE (USD MN)
11.2.1.3.1.3.2. MARKET VOLUME (IU)
11.2.1.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.1.4 OTHERS
11.2.1.3.2. METHOTREXATE, BY BRAND NAME
11.2.1.3.2.1 TREXALL
11.2.1.3.2.1.1. MARKET VALUE (USD MN)
11.2.1.3.2.1.2. MARKET VOLUME (IU)
11.2.1.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.2.2 OTREXUP
11.2.1.3.2.2.1. MARKET VALUE (USD MN)
11.2.1.3.2.2.2. MARKET VOLUME (IU)
11.2.1.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.2.3 RASUVO
11.2.1.3.2.3.1. MARKET VALUE (USD MN)
11.2.1.3.2.3.2. MARKET VOLUME (IU)
11.2.1.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.2.4 OTHERS
11.2.1.3.3. BIOLOGIC DRUGS
11.2.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS
11.2.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.2.1.3.3.1.2. ETANERCEPT, BY BRAND NAME
A. ENBREL
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. ERELZI
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTHERS
11.2.1.3.3.1.3. ADALIMUMAB, BY BRAND
A. HUMIRA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. AMGEVITA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. HYRIMOZ
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
D. OTHERS
11.2.1.3.3.1.4. INFLIXIMAB, BY BRAND
A. REMICADE
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. RENFLEXIS
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTERS
11.2.1.3.3.1.5. GOLIMUMAB, (SIMPONI)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.2.1.3.3.1.6. OTHERS
11.2.1.3.3.2 INTERLEUKIN
11.2.1.3.3.2.1. USTEKINUMAB (STELARA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
11.2.1.3.3.2.2. AVERAGE SELLING PRICE (USD SECUKINUMAB (COSENTYX)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.2.1.3.3.2.3. GUSELKUMAB (TREMFYA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.2.1.3.3.2.4. OTHERS
11.2.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.2.1.3.4. OTHERS
11.2.2 TOPICAL THERAPY
11.2.2.1. VITAMIN D
11.2.2.1.1. CALCIPOTRIENE,BY BRAND
11.2.2.1.1.1 DOVONEX
11.2.2.1.1.1.1. MARKET VALUE (USD MN)
11.2.2.1.1.1.2. MARKET VOLUME (IU)
11.2.2.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.2.2.1.1.2 SORILUX
11.2.2.1.1.2.1. MARKET VALUE (USD MN)
11.2.2.1.1.2.2. MARKET VOLUME (IU)
11.2.2.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.2.2.1.1.3 OTHERS
11.2.2.1.2. CALCITRIOL (VECTICAL)
11.2.2.1.2.1 MARKET VALUE (USD MN)
11.2.2.1.2.2 MARKET VOLUME (IU)
11.2.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.2.2. RETINOIDS (TAZAROTENE), BY BRAND
11.2.2.2.1. TAZORAC
11.2.2.2.1.1 MARKET VALUE (USD MN)
11.2.2.2.1.2 MARKET VOLUME (IU)
11.2.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.2.2.2.2. AVAGE
11.2.2.2.2.1 MARKET VALUE (USD MN)
11.2.2.2.2.2 MARKET VOLUME (IU)
11.2.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.2.2.2.3. OTHERS
11.2.2.3. ANTHRALIN
11.2.2.3.1. MARKET VALUE (USD MN)
11.2.2.3.2. MARKET VOLUME (IU)
11.2.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.2.4. SALICYLIC ACID
11.2.2.4.1. MARKET VALUE (USD MN)
11.2.2.4.2. MARKET VOLUME (IU)
11.2.2.4.3. AVERAGE SELLING PRICE (USD)
11.2.2.5. COAL TAR
11.2.2.5.1. MARKET VALUE (USD MN)
11.2.2.5.2. MARKET VOLUME (IU)
11.2.2.5.3. AVERAGE SELLING PRICE (USD)
11.2.2.6. OTHERS
11.2.3 LIGHT THERAPY
11.2.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)
11.2.3.2. UV B
11.2.3.2.1. BROAD BAND
11.2.3.2.2. NARROW BAND
11.2.3.3. EXCIMER LASER
11.2.4 SYMPTOMATIC MEDICINE
11.2.4.1. ALOE EXTRACT CREAM
11.2.4.1.1. MARKET VALUE (USD MN)
11.2.4.1.2. MARKET VOLUME (IU)
11.2.4.1.3. AVERAGE SELLING PRICE (USD)
11.2.4.2. FISH OIL SUPPLEMENTS
11.2.4.2.1. MARKET VALUE (USD MN)
11.2.4.2.2. MARKET VOLUME (IU)
11.2.4.2.3. AVERAGE SELLING PRICE (USD)
11.2.4.3. OREGON GRAPE
11.2.4.3.1. MARKET VALUE (USD MN)
11.2.4.3.2. MARKET VOLUME (IU)
11.2.4.3.3. AVERAGE SELLING PRICE (USD)
11.3 GUTTATE PSORIASIS
11.3.1 MEDICATION
11.3.1.1. CORTICOSTEROIDS
11.3.1.1.1. HYDROCORTISONE, BY BRAND
11.3.1.1.1.1 HYDROCORT
11.3.1.1.1.1.1. MARKET VALUE (USD MN)
11.3.1.1.1.1.2. MARKET VOLUME (IU)
11.3.1.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.1.2 ALPHOSYL
11.3.1.1.1.2.1. MARKET VALUE (USD MN)
11.3.1.1.1.2.2. MARKET VOLUME (IU)
11.3.1.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.1.3 AQUACORT
11.3.1.1.1.3.1. MARKET VALUE (USD MN)
11.3.1.1.1.3.2. MARKET VOLUME (IU)
11.3.1.1.1.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.1.4 OTHERS
11.3.1.1.2. TRIAMCINOLONE, BY BRAND
11.3.1.1.2.1 KENALOG IV
11.3.1.1.2.1.1. MARKET VALUE (USD MN)
11.3.1.1.2.1.2. MARKET VOLUME (IU)
11.3.1.1.2.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.2.2 ARISTOSPAN
11.3.1.1.2.2.1. MARKET VALUE (USD MN)
11.3.1.1.2.2.2. MARKET VOLUME (IU)
11.3.1.1.2.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.2.3 TRIVARIS
11.3.1.1.2.3.1. MARKET VALUE (USD MN)
11.3.1.1.2.3.2. MARKET VOLUME (IU)
11.3.1.1.2.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.2.4 OTHERS
11.3.1.1.3. CLOBETASOL, BY BRAND
11.3.1.1.3.1 TEMOVATE
11.3.1.1.3.1.1. MARKET VALUE (USD MN)
11.3.1.1.3.1.2. MARKET VOLUME (IU)
11.3.1.1.3.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.3.2 CLOBEX
11.3.1.1.3.2.1. MARKET VALUE (USD MN)
11.3.1.1.3.2.2. MARKET VOLUME (IU)
11.3.1.1.3.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.3.3 OLUX
11.3.1.1.3.3.1. MARKET VALUE (USD MN)
11.3.1.1.3.3.2. MARKET VOLUME (IU)
11.3.1.1.3.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.3.4 OTHERS
11.3.1.2. CALCINEURIN INHIBITORS
11.3.1.2.1. TACROLIMUS, BY BRAND
11.3.1.2.1.1 PROGRAF
11.3.1.2.1.1.1. MARKET VALUE (USD MN)
11.3.1.2.1.1.2. MARKET VOLUME (IU)
11.3.1.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.2.1.2 ENVARSUS XR
11.3.1.2.1.2.1. MARKET VALUE (USD MN)
11.3.1.2.1.2.2. MARKET VOLUME (IU)
11.3.1.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.2.1.3 ASTAGRAF XL
11.3.1.2.1.3.1. MARKET VALUE (USD MN)
11.3.1.2.1.3.2. MARKET VOLUME (IU)
11.3.1.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.2.1.4 OTHERS
11.3.1.2.2. PIMECROLIMUS (ELIDEL)
11.3.1.2.2.1.1. MARKET VALUE (USD MN)
11.3.1.2.2.1.2. MARKET VOLUME (IU)
11.3.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.3. IMMUNOSUPPRESSANT
11.3.1.3.1. CYCLOSPORINE, BY BRAND NAME
11.3.1.3.1.1 SANDMMUNE
11.3.1.3.1.1.1. MARKET VALUE (USD MN)
11.3.1.3.1.1.2. MARKET VOLUME (IU)
11.3.1.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.1.2 NEORAL
11.3.1.3.1.2.1. MARKET VALUE (USD MN)
11.3.1.3.1.2.2. MARKET VOLUME (IU)
11.3.1.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.1.3 RESTASIS
11.3.1.3.1.3.1. MARKET VALUE (USD MN)
11.3.1.3.1.3.2. MARKET VOLUME (IU)
11.3.1.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.1.4 OTHERS
11.3.1.3.2. METHOTREXATE, BY BRAND NAME
11.3.1.3.2.1 TREXALL
11.3.1.3.2.1.1. MARKET VALUE (USD MN)
11.3.1.3.2.1.2. MARKET VOLUME (IU)
11.3.1.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.2.2 OTREXUP
11.3.1.3.2.2.1. MARKET VALUE (USD MN)
11.3.1.3.2.2.2. MARKET VOLUME (IU)
11.3.1.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.2.3 RASUVO
11.3.1.3.2.3.1. MARKET VALUE (USD MN)
11.3.1.3.2.3.2. MARKET VOLUME (IU)
11.3.1.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.2.4 OTHERS
11.3.1.3.3. BIOLOGIC DRUGS
11.3.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS
11.3.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.3.1.2. ETANERCEPT, BY BRAND NAME
A. ENBREL
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. ERELZI
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTHERS
11.3.1.3.3.1.3. ADALIMUMAB, BY BRAND
A. HUMIRA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. AMGEVITA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. HYRIMOZ
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
D. OTHERS
11.3.1.3.3.1.4. INFLIXIMAB, BY BRAND
A. REMICADE
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. RENFLEXIS
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTERS
11.3.1.3.3.1.5. GOLIMUMAB, (SIMPONI)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.3.1.6. OTHERS
11.3.1.3.3.2 INTERLEUKIN
11.3.1.3.3.2.1. USTEKINUMAB (STELARA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.3.2.2. SECUKINUMAB (COSENTYX)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.3.2.3. GUSELKUMAB (TREMFYA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.3.2.4. OTHERS
11.3.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.4. OTHERS
11.3.2 TOPICAL THERAPY
11.3.2.1. VITAMIN D
11.3.2.1.1. CALCIPOTRIENE,BY BRAND
11.3.2.1.1.1 DOVONEX
11.3.2.1.1.1.1. MARKET VALUE (USD MN)
11.3.2.1.1.1.2. MARKET VOLUME (IU)
11.3.2.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.3.2.1.1.2 SORILUX
11.3.2.1.1.2.1. MARKET VALUE (USD MN)
11.3.2.1.1.2.2. MARKET VOLUME (IU)
11.3.2.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.3.2.1.1.3 OTHERS
11.3.2.1.2. CALCITRIOL (VECTICAL)
11.3.2.1.2.1 MARKET VALUE (USD MN)
11.3.2.1.2.2 MARKET VOLUME (IU)
11.3.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.3.2.2. RETINOIDS (TAZAROTENE), BY BRAND
11.3.2.2.1. TAZORAC
11.3.2.2.1.1 MARKET VALUE (USD MN)
11.3.2.2.1.2 MARKET VOLUME (IU)
11.3.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.3.2.2.2. AVAGE
11.3.2.2.2.1 MARKET VALUE (USD MN)
11.3.2.2.2.2 MARKET VOLUME (IU)
11.3.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.3.2.2.3. OTHERS
11.3.2.3. ANTHRALIN
11.3.2.3.1. MARKET VALUE (USD MN)
11.3.2.3.2. MARKET VOLUME (IU)
11.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.3.2.4. SALICYLIC ACID
11.3.2.4.1. MARKET VALUE (USD MN)
11.3.2.4.2. MARKET VOLUME (IU)
11.3.2.4.3. AVERAGE SELLING PRICE (USD)
11.3.2.5. COAL TAR
11.3.2.5.1. MARKET VALUE (USD MN)
11.3.2.5.2. MARKET VOLUME (IU)
11.3.2.5.3. AVERAGE SELLING PRICE (USD)
11.3.2.6. OTHERS
11.3.3 LIGHT THERAPY
11.3.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)
11.3.3.2. UV B
11.3.3.2.1. BROAD BAND
11.3.3.2.2. NARROW BAND
11.3.3.3. EXCIMER LASER
11.3.4 SYMPTOMATIC MEDICINE
11.3.4.1. ALOE EXTRACT CREAM
11.3.4.1.1. MARKET VALUE (USD MN)
11.3.4.1.2. MARKET VOLUME (IU)
11.3.4.1.3. AVERAGE SELLING PRICE (USD)
11.3.4.2. FISH OIL SUPPLEMENTS
11.3.4.2.1. MARKET VALUE (USD MN)
11.3.4.2.2. MARKET VOLUME (IU)
11.3.4.2.3. AVERAGE SELLING PRICE (USD)
11.3.4.3. OREGON GRAPE
11.3.4.3.1. MARKET VALUE (USD MN)
11.3.4.3.2. MARKET VOLUME (IU)
11.3.4.3.3. AVERAGE SELLING PRICE (USD)
11.4 INVERSE PSORIASIS
11.4.1 MEDICATION
11.4.1.1. CORTICOSTEROIDS
11.4.1.1.1. HYDROCORTISONE, BY BRAND
11.4.1.1.1.1 HYDROCORT
11.4.1.1.1.1.1. MARKET VALUE (USD MN)
11.4.1.1.1.1.2. MARKET VOLUME (IU)
11.4.1.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.1.2 ALPHOSYL
11.4.1.1.1.2.1. MARKET VALUE (USD MN)
11.4.1.1.1.2.2. MARKET VOLUME (IU)
11.4.1.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.1.3 AQUACORT
11.4.1.1.1.3.1. MARKET VALUE (USD MN)
11.4.1.1.1.3.2. MARKET VOLUME (IU)
11.4.1.1.1.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.1.4 OTHERS
11.4.1.1.2. TRIAMCINOLONE, BY BRAND
11.4.1.1.2.1 KENALOG IV
11.4.1.1.2.1.1. MARKET VALUE (USD MN)
11.4.1.1.2.1.2. MARKET VOLUME (IU)
11.4.1.1.2.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.2.2 ARISTOSPAN
11.4.1.1.2.2.1. MARKET VALUE (USD MN)
11.4.1.1.2.2.2. MARKET VOLUME (IU)
11.4.1.1.2.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.2.3 TRIVARIS
11.4.1.1.2.3.1. MARKET VALUE (USD MN)
11.4.1.1.2.3.2. MARKET VOLUME (IU)
11.4.1.1.2.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.2.4 OTHERS
11.4.1.1.3. CLOBETASOL, BY BRAND
11.4.1.1.3.1 TEMOVATE
11.4.1.1.3.1.1. MARKET VALUE (USD MN)
11.4.1.1.3.1.2. MARKET VOLUME (IU)
11.4.1.1.3.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.3.2 CLOBEX
11.4.1.1.3.2.1. MARKET VALUE (USD MN)
11.4.1.1.3.2.2. MARKET VOLUME (IU)
11.4.1.1.3.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.3.3 OLUX
11.4.1.1.3.3.1. MARKET VALUE (USD MN)
11.4.1.1.3.3.2. MARKET VOLUME (IU)
11.4.1.1.3.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.3.4 OTHERS
11.4.1.2. CALCINEURIN INHIBITORS
11.4.1.2.1. TACROLIMUS, BY BRAND
11.4.1.2.1.1 PROGRAF
11.4.1.2.1.1.1. MARKET VALUE (USD MN)
11.4.1.2.1.1.2. MARKET VOLUME (IU)
11.4.1.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.2.1.2 ENVARSUS XR
11.4.1.2.1.2.1. MARKET VALUE (USD MN)
11.4.1.2.1.2.2. MARKET VOLUME (IU)
11.4.1.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.2.1.3 ASTAGRAF XL
11.4.1.2.1.3.1. MARKET VALUE (USD MN)
11.4.1.2.1.3.2. MARKET VOLUME (IU)
11.4.1.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.2.1.4 OTHERS
11.4.1.2.2. PIMECROLIMUS (ELIDEL)
11.4.1.2.2.1.1. MARKET VALUE (USD MN)
11.4.1.2.2.1.2. MARKET VOLUME (IU)
11.4.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.3. IMMUNOSUPPRESSANT
11.4.1.3.1. CYCLOSPORINE, BY BRAND NAME
11.4.1.3.1.1 SANDMMUNE
11.4.1.3.1.1.1. MARKET VALUE (USD MN)
11.4.1.3.1.1.2. MARKET VOLUME (IU)
11.4.1.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.1.2 NEORAL
11.4.1.3.1.2.1. MARKET VALUE (USD MN)
11.4.1.3.1.2.2. MARKET VOLUME (IU)
11.4.1.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.1.3 RESTASIS
11.4.1.3.1.3.1. MARKET VALUE (USD MN)
11.4.1.3.1.3.2. MARKET VOLUME (IU)
11.4.1.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.1.4 OTHERS
11.4.1.3.2. METHOTREXATE, BY BRAND NAME
11.4.1.3.2.1 TREXALL
11.4.1.3.2.1.1. MARKET VALUE (USD MN)
11.4.1.3.2.1.2. MARKET VOLUME (IU)
11.4.1.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.2.2 OTREXUP
11.4.1.3.2.2.1. MARKET VALUE (USD MN)
11.4.1.3.2.2.2. MARKET VOLUME (IU)
11.4.1.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.2.3 RASUVO
11.4.1.3.2.3.1. MARKET VALUE (USD MN)
11.4.1.3.2.3.2. MARKET VOLUME (IU)
11.4.1.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.2.4 OTHERS
11.4.1.3.3. BIOLOGIC DRUGS
11.4.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS
11.4.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.3.1.2. ETANERCEPT, BY BRAND NAME
A. ENBREL
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. ERELZI
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTHERS
11.4.1.3.3.1.3. ADALIMUMAB, BY BRAND
A. HUMIRA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. AMGEVITA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. HYRIMOZ
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
D. OTHERS
11.4.1.3.3.1.4. INFLIXIMAB, BY BRAND
A. REMICADE
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. RENFLEXIS
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTERS
11.4.1.3.3.1.5. GOLIMUMAB, (SIMPONI)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.3.1.6. OTHERS
11.4.1.3.3.2 INTERLEUKIN
11.4.1.3.3.2.1. USTEKINUMAB (STELARA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.3.2.2. SECUKINUMAB (COSENTYX)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.3.2.3. GUSELKUMAB (TREMFYA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.3.2.4. OTHERS
11.4.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.4. OTHERS
11.4.2 TOPICAL THERAPY
11.4.2.1. VITAMIN D
11.4.2.1.1. CALCIPOTRIENE,BY BRAND
11.4.2.1.1.1 DOVONEX
11.4.2.1.1.1.1. MARKET VALUE (USD MN)
11.4.2.1.1.1.2. MARKET VOLUME (IU)
11.4.2.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.4.2.1.1.2 SORILUX
11.4.2.1.1.2.1. MARKET VALUE (USD MN)
11.4.2.1.1.2.2. MARKET VOLUME (IU)
11.4.2.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.4.2.1.1.3 OTHERS
11.4.2.1.2. CALCITRIOL (VECTICAL)
11.4.2.1.2.1 MARKET VALUE (USD MN)
11.4.2.1.2.2 MARKET VOLUME (IU)
11.4.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.4.2.2. RETINOIDS (TAZAROTENE), BY BRAND
11.4.2.2.1. TAZORAC
11.4.2.2.1.1 MARKET VALUE (USD MN)
11.4.2.2.1.2 MARKET VOLUME (IU)
11.4.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.4.2.2.2. AVAGE
11.4.2.2.2.1 MARKET VALUE (USD MN)
11.4.2.2.2.2 MARKET VOLUME (IU)
11.4.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.4.2.2.3. OTHERS
11.4.2.3. ANTHRALIN
11.4.2.3.1. MARKET VALUE (USD MN)
11.4.2.3.2. MARKET VOLUME (IU)
11.4.2.3.3. AVERAGE SELLING PRICE (USD)
11.4.2.4. SALICYLIC ACID
11.4.2.4.1. MARKET VALUE (USD MN)
11.4.2.4.2. MARKET VOLUME (IU)
11.4.2.4.3. AVERAGE SELLING PRICE (USD)
11.4.2.5. COAL TAR
11.4.2.5.1. MARKET VALUE (USD MN)
11.4.2.5.2. MARKET VOLUME (IU)
11.4.2.5.3. AVERAGE SELLING PRICE (USD)
11.4.2.6. OTHERS
11.4.3 LIGHT THERAPY
11.4.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)
11.4.3.2. UV B
11.4.3.2.1. BROAD BAND
11.4.3.2.2. NARROW BAND
11.4.3.3. EXCIMER LASER
11.4.4 SYMPTOMATIC MEDICINE
11.4.4.1. ALOE EXTRACT CREAM
11.4.4.1.1. MARKET VALUE (USD MN)
11.4.4.1.2. MARKET VOLUME (IU)
11.4.4.1.3. AVERAGE SELLING PRICE (USD)
11.4.4.2. FISH OIL SUPPLEMENTS
11.4.4.2.1. MARKET VALUE (USD MN)
11.4.4.2.2. MARKET VOLUME (IU)
11.4.4.2.3. AVERAGE SELLING PRICE (USD)
11.4.4.3. OREGON GRAPE
11.4.4.3.1. MARKET VALUE (USD MN)
11.4.4.3.2. MARKET VOLUME (IU)
11.4.4.3.3. AVERAGE SELLING PRICE (USD)
11.5 PUSTULAR PSORIASIS
11.5.1 MEDICATION
11.5.1.1. CORTICOSTEROIDS
11.5.1.1.1. HYDROCORTISONE, BY BRAND
11.5.1.1.1.1 HYDROCORT
11.5.1.1.1.1.1. MARKET VALUE (USD MN)
11.5.1.1.1.1.2. MARKET VOLUME (IU)
11.5.1.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.1.2 ALPHOSYL
11.5.1.1.1.2.1. MARKET VALUE (USD MN)
11.5.1.1.1.2.2. MARKET VOLUME (IU)
11.5.1.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.1.3 AQUACORT
11.5.1.1.1.3.1. MARKET VALUE (USD MN)
11.5.1.1.1.3.2. MARKET VOLUME (IU)
11.5.1.1.1.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.1.4 OTHERS
11.5.1.1.2. TRIAMCINOLONE, BY BRAND
11.5.1.1.2.1 KENALOG IV
11.5.1.1.2.1.1. MARKET VALUE (USD MN)
11.5.1.1.2.1.2. MARKET VOLUME (IU)
11.5.1.1.2.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.2.2 ARISTOSPAN
11.5.1.1.2.2.1. MARKET VALUE (USD MN)
11.5.1.1.2.2.2. MARKET VOLUME (IU)
11.5.1.1.2.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.2.3 TRIVARIS
11.5.1.1.2.3.1. MARKET VALUE (USD MN)
11.5.1.1.2.3.2. MARKET VOLUME (IU)
11.5.1.1.2.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.2.4 OTHERS
11.5.1.1.3. CLOBETASOL, BY BRAND
11.5.1.1.3.1 TEMOVATE
11.5.1.1.3.1.1. MARKET VALUE (USD MN)
11.5.1.1.3.1.2. MARKET VOLUME (IU)
11.5.1.1.3.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.3.2 CLOBEX
11.5.1.1.3.2.1. MARKET VALUE (USD MN)
11.5.1.1.3.2.2. MARKET VOLUME (IU)
11.5.1.1.3.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.3.3 OLUX
11.5.1.1.3.3.1. MARKET VALUE (USD MN)
11.5.1.1.3.3.2. MARKET VOLUME (IU)
11.5.1.1.3.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.3.4 OTHERS
11.5.1.2. CALCINEURIN INHIBITORS
11.5.1.2.1. TACROLIMUS, BY BRAND
11.5.1.2.1.1 PROGRAF
11.5.1.2.1.1.1. MARKET VALUE (USD MN)
11.5.1.2.1.1.2. MARKET VOLUME (IU)
11.5.1.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.2.1.2 ENVARSUS XR
11.5.1.2.1.2.1. MARKET VALUE (USD MN)
11.5.1.2.1.2.2. MARKET VOLUME (IU)
11.5.1.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.2.1.3 ASTAGRAF XL
11.5.1.2.1.3.1. MARKET VALUE (USD MN)
11.5.1.2.1.3.2. MARKET VOLUME (IU)
11.5.1.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.2.1.4 OTHERS
11.5.1.2.2. PIMECROLIMUS (ELIDEL)
11.5.1.2.2.1.1. MARKET VALUE (USD MN)
11.5.1.2.2.1.2. MARKET VOLUME (IU)
11.5.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.3. IMMUNOSUPPRESSANT
11.5.1.3.1. CYCLOSPORINE, BY BRAND NAME
11.5.1.3.1.1 SANDMMUNE
11.5.1.3.1.1.1. MARKET VALUE (USD MN)
11.5.1.3.1.1.2. MARKET VOLUME (IU)
11.5.1.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.1.2 NEORAL
11.5.1.3.1.2.1. MARKET VALUE (USD MN)
11.5.1.3.1.2.2. MARKET VOLUME (IU)
11.5.1.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.1.3 RESTASIS
11.5.1.3.1.3.1. MARKET VALUE (USD MN)
11.5.1.3.1.3.2. MARKET VOLUME (IU)
11.5.1.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.1.4 OTHERS
11.5.1.3.2. METHOTREXATE, BY BRAND NAME
11.5.1.3.2.1 TREXALL
11.5.1.3.2.1.1. MARKET VALUE (USD MN)
11.5.1.3.2.1.2. MARKET VOLUME (IU)
11.5.1.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.2.2 OTREXUP
11.5.1.3.2.2.1. MARKET VALUE (USD MN)
11.5.1.3.2.2.2. MARKET VOLUME (IU)
11.5.1.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.2.3 RASUVO
11.5.1.3.2.3.1. MARKET VALUE (USD MN)
11.5.1.3.2.3.2. MARKET VOLUME (IU)
11.5.1.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.2.4 OTHERS
11.5.1.3.3. BIOLOGIC DRUGS
11.5.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS
11.5.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.3.1.2. ETANERCEPT, BY BRAND NAME
A. ENBREL
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. ERELZI
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTHERS
11.5.1.3.3.1.3. ADALIMUMAB, BY BRAND
A. HUMIRA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. AMGEVITA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. HYRIMOZ
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
D. OTHERS
11.5.1.3.3.1.4. INFLIXIMAB, BY BRAND
A. REMICADE
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. RENFLEXIS
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTERS
11.5.1.3.3.1.5. GOLIMUMAB, (SIMPONI)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.3.1.6. OTHERS
11.5.1.3.3.2 INTERLEUKIN
11.5.1.3.3.2.1. USTEKINUMAB (STELARA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.3.2.2. SECUKINUMAB (COSENTYX)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.3.2.3. GUSELKUMAB (TREMFYA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.3.2.4. OTHERS
11.5.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.4. OTHERS
11.5.2 TOPICAL THERAPY
11.5.2.1. VITAMIN D
11.5.2.1.1. CALCIPOTRIENE,BY BRAND
11.5.2.1.1.1 DOVONEX
11.5.2.1.1.1.1. MARKET VALUE (USD MN)
11.5.2.1.1.1.2. MARKET VOLUME (IU)
11.5.2.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.5.2.1.1.2 SORILUX
11.5.2.1.1.2.1. MARKET VALUE (USD MN)
11.5.2.1.1.2.2. MARKET VOLUME (IU)
11.5.2.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.5.2.1.1.3 OTHERS
11.5.2.1.2. CALCITRIOL (VECTICAL)
11.5.2.1.2.1 MARKET VALUE (USD MN)
11.5.2.1.2.2 MARKET VOLUME (IU)
11.5.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.5.2.2. RETINOIDS (TAZAROTENE), BY BRAND
11.5.2.2.1. TAZORAC
11.5.2.2.1.1 MARKET VALUE (USD MN)
11.5.2.2.1.2 MARKET VOLUME (IU)
11.5.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.5.2.2.2. AVAGE
11.5.2.2.2.1 MARKET VALUE (USD MN)
11.5.2.2.2.2 MARKET VOLUME (IU)
11.5.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.5.2.2.3. OTHERS
11.5.2.3. ANTHRALIN
11.5.2.3.1. MARKET VALUE (USD MN)
11.5.2.3.2. MARKET VOLUME (IU)
11.5.2.3.3. AVERAGE SELLING PRICE (USD)
11.5.2.4. SALICYLIC ACID
11.5.2.4.1. MARKET VALUE (USD MN)
11.5.2.4.2. MARKET VOLUME (IU)
11.5.2.4.3. AVERAGE SELLING PRICE (USD)
11.5.2.5. COAL TAR
11.5.2.5.1. MARKET VALUE (USD MN)
11.5.2.5.2. MARKET VOLUME (IU)
11.5.2.5.3. AVERAGE SELLING PRICE (USD)
11.5.2.6. OTHERS
11.5.3 LIGHT THERAPY
11.5.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)
11.5.3.2. UV B
11.5.3.2.1. BROAD BAND
11.5.3.2.2. NARROW BAND
11.5.3.3. EXCIMER LASER
11.5.4 SYMPTOMATIC MEDICINE
11.5.4.1. ALOE EXTRACT CREAM
11.5.4.1.1. MARKET VALUE (USD MN)
11.5.4.1.2. MARKET VOLUME (IU)
11.5.4.1.3. AVERAGE SELLING PRICE (USD)
11.5.4.2. FISH OIL SUPPLEMENTS
11.5.4.2.1. MARKET VALUE (USD MN)
11.5.4.2.2. MARKET VOLUME (IU)
11.5.4.2.3. AVERAGE SELLING PRICE (USD)
11.5.4.3. OREGON GRAPE
11.5.4.3.1. MARKET VALUE (USD MN)
11.5.4.3.2. MARKET VOLUME (IU)
11.5.4.3.3. AVERAGE SELLING PRICE (USD)
11.6 ERYTHRODERMIC PSORIASIS
11.6.1 MEDICATION
11.6.1.1. CORTICOSTEROIDS
11.6.1.1.1. HYDROCORTISONE, BY BRAND
11.6.1.1.1.1 HYDROCORT
11.6.1.1.1.1.1. MARKET VALUE (USD MN)
11.6.1.1.1.1.2. MARKET VOLUME (IU)
11.6.1.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.1.2 ALPHOSYL
11.6.1.1.1.2.1. MARKET VALUE (USD MN)
11.6.1.1.1.2.2. MARKET VOLUME (IU)
11.6.1.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.1.3 AQUACORT
11.6.1.1.1.3.1. MARKET VALUE (USD MN)
11.6.1.1.1.3.2. MARKET VOLUME (IU)
11.6.1.1.1.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.1.4 OTHERS
11.6.1.1.2. TRIAMCINOLONE, BY BRAND
11.6.1.1.2.1 KENALOG IV
11.6.1.1.2.1.1. MARKET VALUE (USD MN)
11.6.1.1.2.1.2. MARKET VOLUME (IU)
11.6.1.1.2.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.2.2 ARISTOSPAN
11.6.1.1.2.2.1. MARKET VALUE (USD MN)
11.6.1.1.2.2.2. MARKET VOLUME (IU)
11.6.1.1.2.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.2.3 TRIVARIS
11.6.1.1.2.3.1. MARKET VALUE (USD MN)
11.6.1.1.2.3.2. MARKET VOLUME (IU)
11.6.1.1.2.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.2.4 OTHERS
11.6.1.1.3. CLOBETASOL, BY BRAND
11.6.1.1.3.1 TEMOVATE
11.6.1.1.3.1.1. MARKET VALUE (USD MN)
11.6.1.1.3.1.2. MARKET VOLUME (IU)
11.6.1.1.3.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.3.2 CLOBEX
11.6.1.1.3.2.1. MARKET VALUE (USD MN)
11.6.1.1.3.2.2. MARKET VOLUME (IU)
11.6.1.1.3.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.3.3 OLUX
11.6.1.1.3.3.1. MARKET VALUE (USD MN)
11.6.1.1.3.3.2. MARKET VOLUME (IU)
11.6.1.1.3.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.3.4 OTHERS
11.6.1.2. CALCINEURIN INHIBITORS
11.6.1.2.1. TACROLIMUS, BY BRAND
11.6.1.2.1.1 PROGRAF
11.6.1.2.1.1.1. MARKET VALUE (USD MN)
11.6.1.2.1.1.2. MARKET VOLUME (IU)
11.6.1.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.2.1.2 ENVARSUS XR
11.6.1.2.1.2.1. MARKET VALUE (USD MN)
11.6.1.2.1.2.2. MARKET VOLUME (IU)
11.6.1.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.2.1.3 ASTAGRAF XL
11.6.1.2.1.3.1. MARKET VALUE (USD MN)
11.6.1.2.1.3.2. MARKET VOLUME (IU)
11.6.1.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.2.1.4 OTHERS
11.6.1.2.2. PIMECROLIMUS (ELIDEL)
11.6.1.2.2.1.1. MARKET VALUE (USD MN)
11.6.1.2.2.1.2. MARKET VOLUME (IU)
11.6.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.3. IMMUNOSUPPRESSANT
11.6.1.3.1. CYCLOSPORINE, BY BRAND NAME
11.6.1.3.1.1 SANDMMUNE
11.6.1.3.1.1.1. MARKET VALUE (USD MN)
11.6.1.3.1.1.2. MARKET VOLUME (IU)
11.6.1.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.1.2 NEORAL
11.6.1.3.1.2.1. MARKET VALUE (USD MN)
11.6.1.3.1.2.2. MARKET VOLUME (IU)
11.6.1.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.1.3 RESTASIS
11.6.1.3.1.3.1. MARKET VALUE (USD MN)
11.6.1.3.1.3.2. MARKET VOLUME (IU)
11.6.1.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.1.4 OTHERS
11.6.1.3.2. METHOTREXATE, BY BRAND NAME
11.6.1.3.2.1 TREXALL
11.6.1.3.2.1.1. MARKET VALUE (USD MN)
11.6.1.3.2.1.2. MARKET VOLUME (IU)
11.6.1.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.2.2 OTREXUP
11.6.1.3.2.2.1. MARKET VALUE (USD MN)
11.6.1.3.2.2.2. MARKET VOLUME (IU)
11.6.1.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.2.3 RASUVO
11.6.1.3.2.3.1. MARKET VALUE (USD MN)
11.6.1.3.2.3.2. MARKET VOLUME (IU)
11.6.1.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.2.4 OTHERS
11.6.1.3.3. BIOLOGIC DRUGS
11.6.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS
11.6.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.3.1.2. ETANERCEPT, BY BRAND NAME
A. ENBREL
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. ERELZI
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTHERS
11.6.1.3.3.1.3. ADALIMUMAB, BY BRAND
A. HUMIRA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. AMGEVITA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. HYRIMOZ
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
D. OTHERS
11.6.1.3.3.1.4. INFLIXIMAB, BY BRAND
A. REMICADE
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. RENFLEXIS
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTERS
11.6.1.3.3.1.5. GOLIMUMAB, (SIMPONI)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.3.1.6. OTHERS
11.6.1.3.3.2 INTERLEUKIN
11.6.1.3.3.2.1. USTEKINUMAB (STELARA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.3.2.2. SECUKINUMAB (COSENTYX)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.3.2.3. GUSELKUMAB (TREMFYA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.3.2.4. OTHERS
11.6.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.4. OTHERS
11.6.2 TOPICAL THERAPY
11.6.2.1. VITAMIN D
11.6.2.1.1. CALCIPOTRIENE,BY BRAND
11.6.2.1.1.1 DOVONEX
11.6.2.1.1.1.1. MARKET VALUE (USD MN)
11.6.2.1.1.1.2. MARKET VOLUME (IU)
11.6.2.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.6.2.1.1.2 SORILUX
11.6.2.1.1.2.1. MARKET VALUE (USD MN)
11.6.2.1.1.2.2. MARKET VOLUME (IU)
11.6.2.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.6.2.1.1.3 OTHERS
11.6.2.1.2. CALCITRIOL (VECTICAL)
11.6.2.1.2.1 MARKET VALUE (USD MN)
11.6.2.1.2.2 MARKET VOLUME (IU)
11.6.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.6.2.2. RETINOIDS (TAZAROTENE), BY BRAND
11.6.2.2.1. TAZORAC
11.6.2.2.1.1 MARKET VALUE (USD MN)
11.6.2.2.1.2 MARKET VOLUME (IU)
11.6.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.6.2.2.2. AVAGE
11.6.2.2.2.1 MARKET VALUE (USD MN)
11.6.2.2.2.2 MARKET VOLUME (IU)
11.6.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.6.2.2.3. OTHERS
11.6.2.3. ANTHRALIN
11.6.2.3.1. MARKET VALUE (USD MN)
11.6.2.3.2. MARKET VOLUME (IU)
11.6.2.3.3. AVERAGE SELLING PRICE (USD)
11.6.2.4. SALICYLIC ACID
11.6.2.4.1. MARKET VALUE (USD MN)
11.6.2.4.2. MARKET VOLUME (IU)
11.6.2.4.3. AVERAGE SELLING PRICE (USD)
11.6.2.5. COAL TAR
11.6.2.5.1. MARKET VALUE (USD MN)
11.6.2.5.2. MARKET VOLUME (IU)
11.6.2.5.3. AVERAGE SELLING PRICE (USD)
11.6.2.6. OTHERS
11.6.3 LIGHT THERAPY
11.6.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)
11.6.3.2. UV B
11.6.3.2.1. BROAD BAND
11.6.3.2.2. NARROW BAND
11.6.3.3. EXCIMER LASER
11.6.4 SYMPTOMATIC MEDICINE
11.6.4.1. ALOE EXTRACT CREAM
11.6.4.1.1. MARKET VALUE (USD MN)
11.6.4.1.2. MARKET VOLUME (IU)
11.6.4.1.3. AVERAGE SELLING PRICE (USD)
11.6.4.2. FISH OIL SUPPLEMENTS
11.6.4.2.1. MARKET VALUE (USD MN)
11.6.4.2.2. MARKET VOLUME (IU)
11.6.4.2.3. AVERAGE SELLING PRICE (USD)
11.6.4.3. OREGON GRAPE
11.6.4.3.1. MARKET VALUE (USD MN)
11.6.4.3.2. MARKET VOLUME (IU)
11.6.4.3.3. AVERAGE SELLING PRICE (USD)
12 GLOBAL PSORIASIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.2.1 TABLETS
12.2.2 PILLS
12.2.3 OTHERS
12.3 PARENTERAL
12.3.1 INTRAVENOUS
12.3.2 SUBCUTANEOUS
12.3.3 OTHERS
12.4 TOPICAL
12.4.1 GEL
12.4.2 CREAM
12.4.3 FOAM
12.4.4 OINTMENTS
12.4.5 SPRAY
12.4.6 SHAMPOO
12.4.7 LOTION
12.4.8 OTHERS
13 GLOBAL PSORIASIS TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 THERAPY CENTERS
13.6 OTHERS
14 GLOBAL PSORIASIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 HOSPITAL PHARMACY
14.4 RETAIL PHARMACY
14.5 ONLINE PHARMACY
14.6 OTHERS
15 GLOBAL PSORIASIS TREATMENT MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15.5 MERGERS & ACQUISITIONS
15.6 NEW PRODUCT DEVELOPMENT & APPROVALS
15.7 EXPANSIONS
15.8 REGULATORY CHANGES
15.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
16 GLOBAL PSORIASIS TREATMENT MARKET, BY GEOGRAPHY
16.1 GLOBAL PSORIASIS TREATMENT MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
16.2 NORTH AMERICA
16.2.1 U.S.
16.2.1.1. U.S. PSORIASIS TREATMENT MARKET, BY TYPE
16.2.1.2. U.S. PSORIASIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
16.2.1.3. U.S. PSORIASIS TREATMENT MARKET, BY END USER
16.2.1.4. U.S. PSORIASIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.3 CANADA
16.3.1 MEXICO
16.3.2 DOMINICAN REPUBLIC
16.3.3 JAMAICA
16.3.4 PANAMA
16.4 EUROPE
16.4.1 GERMANY
16.4.2 FRANCE
16.4.3 U.K.
16.4.4 HUNGARY
16.4.5 LITHUANIA
16.4.6 AUSTRIA
16.4.7 IRELAND
16.4.8 NORWAY
16.4.9 POLAND
16.4.10 ITALY
16.4.11 SPAIN
16.4.12 RUSSIA
16.4.13 TURKEY
16.4.14 NETHERLANDS
16.4.15 SWITZERLAND
16.4.16 REST OF EUROPE
16.5 ASIA-PACIFIC
16.5.1 JAPAN
16.5.2 CHINA
16.5.3 TAIWAN
16.5.4 SOUTH KOREA
16.5.5 INDIA
16.5.6 AUSTRALIA
16.5.7 SINGAPORE
16.5.8 THAILAND
16.5.9 MALAYSIA
16.5.10 INDONESIA
16.5.11 PHILIPPINES
16.5.12 VIETNAM
16.5.13 REST OF ASIA-PACIFIC
16.6 SOUTH AMERICA
16.6.1 BRAZIL
16.6.2 ECUADOR
16.6.3 CHILE
16.6.4 COLOMBIA
16.6.5 VENEZUELA
16.6.6 ARGENTINA
16.6.7 PERU
16.6.8 CURAÇAO
16.6.9 PARAGUAY
16.6.10 URUGUAY
16.6.11 TRINIDAD AND TOBAGO
16.6.12 REST OF SOUTH AMERICA
16.7 MIDDLE EAST AND AFRICA
16.7.1 SOUTH AFRICA
16.7.2 SAUDI ARABIA
16.7.3 UAE
16.7.4 EGYPT
16.7.5 KUWAIT
16.7.6 ISRAEL
16.7.7 BOLIVIA
16.7.8 REST OF MIDDLE EAST AND AFRICA
16.7.9 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
17 GLOBAL PSORIASIS TREATMENT MARKET, SWOT AND DBMR ANALYSIS
18 GLOBAL PSORIASIS TREATMENT MARKET, COMPANY PROFILE
18.1 PERRIGO COMPANY PLC
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 SANOFI
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 GLAXOSMITHKLINE
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 MERCK & CO, INC
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 F-HOFFMANN LA ROCHE
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 PFIZER
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPMENTS
18.7 JOHNSON & JOHNSON
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPMENTS
18.8 COSETTE PHARMACEUTICALS, INC.
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPMENTS
18.9 LUPIN
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPMENTS
18.9.6 MYLAN N.V.
18.9.7 COMPANY OVERVIEW
18.9.8 REVENUE ANALYSIS
18.9.9 GEOGRAPHIC PRESENCE
18.9.10 PRODUCT PORTFOLIO
18.9.11 RECENT DEVELOPMENTS
18.1 WOCKHARDT
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPMENTS
18.11 TOLMAR PHARMACEUTICALS, INC.
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPMENTS
18.12 AKORN, INCORPORATED
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPMENTS
18.13 TELIGENT
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPMENTS
18.14 GLENMARK PHARMACEUTICAL INC.
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPMENTS
18.15 XIROMED
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPMENTS
18.16 AMNEAL PHARMACEUTICALS LLC
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPMENTS
18.17 ENCUBE ETHICALS
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENTS
18.18 INGENUS PHARMACEUTICALS, LLC
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPMENTS
18.19 ALEOR DERMACEUTICALS LIMITED
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPMENTS
18.2 SANDOZ AG
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPMENTS
18.21 ENCORE DERMATOLOGY, INC.,
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPMENTS
18.22 ZYDUS PHARMACEUTICALS, INC.
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPMENTS
18.23 TEVA PHARMACEUTICALS USA, INC.
18.23.1 COMPANY OVERVIEW
18.23.2 REVENUE ANALYSIS
18.23.3 GEOGRAPHIC PRESENCE
18.23.4 PRODUCT PORTFOLIO
18.23.5 RECENT DEVELOPMENTS
18.24 STIEFEL LABORATORIES, INC.
18.24.1 COMPANY OVERVIEW
18.24.2 REVENUE ANALYSIS
18.24.3 GEOGRAPHIC PRESENCE
18.24.4 PRODUCT PORTFOLIO
18.24.5 RECENT DEVELOPMENTS
18.25 SIGMAPHARM LABORATORIES, LLC.
18.25.1 COMPANY OVERVIEW
18.25.2 REVENUE ANALYSIS
18.25.3 GEOGRAPHIC PRESENCE
18.25.4 PRODUCT PORTFOLIO
18.25.5 RECENT DEVELOPMENTS
18.26 THE DAAVLIN COMPANY
18.26.1 COMPANY OVERVIEW
18.26.2 REVENUE ANALYSIS
18.26.3 GEOGRAPHIC PRESENCE
18.26.4 PRODUCT PORTFOLIO
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19 RELATED REPORTS
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
